Werth Ventures

DeepLook Medical develops medical imaging software that uses shape-recognition to extract radiomic features from mammography images, revealing tissue morphology not visible to the unaided eye, and aims to improve early breast cancer detection, particularly in dense breast tissue, by identifying subtle data within radiological images and presenting features beyond human vision to help clinicians and reduce unnecessary procedures by lowering false positives.

Cingulate Therapeutics, LLC is a biopharmaceutical company focused on developing innovative treatments for central nervous system and neurobiological disorders, particularly Attention Deficit and Hyperactivity Disorder (ADHD). Established in 2012 and headquartered in Kansas City, Kansas, with an additional office in Morristown, New Jersey, Cingulate is advancing two first-line stimulant medications, CTx-1301 and CTx-1302, designed for comprehensive patient use across all age groups. Utilizing a unique delivery technology, these medications aim to provide rapid onset of action, extended duration of effect, and favorable tolerability in a once-daily oral formulation. The company has partnered with Catalent Pharma Solutions to leverage their OptiDose technology, enhancing manufacturing efficiency and drug delivery. Cingulate's approach addresses significant gaps in the current ADHD treatment landscape, particularly the need for full-day therapeutic efficacy, and targets a substantial market opportunity projected to be worth $2-$3 billion in the combination-dose segment and $9 billion overall.

Cingulate Therapeutics, LLC is a biopharmaceutical company focused on developing innovative treatments for central nervous system and neurobiological disorders, particularly Attention Deficit and Hyperactivity Disorder (ADHD). Established in 2012 and headquartered in Kansas City, Kansas, with an additional office in Morristown, New Jersey, Cingulate is advancing two first-line stimulant medications, CTx-1301 and CTx-1302, designed for comprehensive patient use across all age groups. Utilizing a unique delivery technology, these medications aim to provide rapid onset of action, extended duration of effect, and favorable tolerability in a once-daily oral formulation. The company has partnered with Catalent Pharma Solutions to leverage their OptiDose technology, enhancing manufacturing efficiency and drug delivery. Cingulate's approach addresses significant gaps in the current ADHD treatment landscape, particularly the need for full-day therapeutic efficacy, and targets a substantial market opportunity projected to be worth $2-$3 billion in the combination-dose segment and $9 billion overall.

Cingulate Therapeutics, LLC is a biopharmaceutical company focused on developing innovative treatments for central nervous system and neurobiological disorders, particularly Attention Deficit and Hyperactivity Disorder (ADHD). Established in 2012 and headquartered in Kansas City, Kansas, with an additional office in Morristown, New Jersey, Cingulate is advancing two first-line stimulant medications, CTx-1301 and CTx-1302, designed for comprehensive patient use across all age groups. Utilizing a unique delivery technology, these medications aim to provide rapid onset of action, extended duration of effect, and favorable tolerability in a once-daily oral formulation. The company has partnered with Catalent Pharma Solutions to leverage their OptiDose technology, enhancing manufacturing efficiency and drug delivery. Cingulate's approach addresses significant gaps in the current ADHD treatment landscape, particularly the need for full-day therapeutic efficacy, and targets a substantial market opportunity projected to be worth $2-$3 billion in the combination-dose segment and $9 billion overall.

Torigen Pharmaceuticals is a company dedicated to advancing cancer care solutions for companion animals. Founded in 2013 by Ashley Kalinauskas and Mark Suckow, the company is based in Farmington, Connecticut. Torigen focuses on developing innovative immunotherapy treatments, including an experimental autologous cancer vaccine that activates the immune system to target specific tumor-associated antigens on cancer cells. This approach aims to enable veterinarians to detect and treat cancer in animals more effectively, reducing the reliance on invasive surgeries and chemotherapy. By leveraging existing scientific research, Torigen seeks to improve outcomes for pets diagnosed with cancer, enhancing their quality of life through novel therapeutic strategies.

Bastion Health is a digital clinic focused on men's health, combining advanced software and hardware technologies to provide at-home diagnostics and virtual specialty care. Established in 2018 and based in Farmington, Connecticut, the company offers a comprehensive suite of services, including consultations and treatments for prostate health, reproductive issues, hormonal balance, and early cancer detection. Bastion Health aims to enhance accessibility and affordability in men's healthcare by connecting patients with a network of virtual urologists and medical professionals. Its mobile application facilitates better engagement and navigation through the healthcare system, allowing men to take an active role in improving their health and lifestyle. By streamlining access to specialized care, Bastion Health not only optimizes health outcomes for patients but also presents significant cost savings for employers.

VeraDermics is a dermatology company focused on developing innovative drug delivery systems to address skin conditions, particularly warts. The company has created a dissolvable microneedle patch that allows for the painless administration of immunotherapy, which harnesses the body's immune response to combat the wart virus. This patch is designed for easy application, functioning like a bandage and remaining on the skin for less than an hour. During this time, microneedles made from immune stimulators dissolve from the patch into the skin, providing a sustained release of treatment over several weeks. By offering a straightforward and effective solution, VeraDermics aims to enhance patient experiences and outcomes in dermatological care.

MedRhythms Inc. is a neuro-rehabilitation company that specializes in neurologic music therapy, employing sensors, music, and artificial intelligence to create evidence-based interventions aimed at enhancing walking and overall functional outcomes. Founded in 2015 and headquartered in Portland, Maine, the company addresses the needs of individuals affected by neurological conditions such as traumatic brain injury, stroke, Parkinson’s disease, and Huntington’s disease. By merging music with neuroscience and technology, MedRhythms develops programs that focus on sensorimotor, speech, language, and cognitive rehabilitation goals, allowing patients to leverage music as a therapeutic tool to stimulate brain function and improve their quality of life.

Bastion Health is a digital clinic focused on men's health, combining advanced software and hardware technologies to provide at-home diagnostics and virtual specialty care. Established in 2018 and based in Farmington, Connecticut, the company offers a comprehensive suite of services, including consultations and treatments for prostate health, reproductive issues, hormonal balance, and early cancer detection. Bastion Health aims to enhance accessibility and affordability in men's healthcare by connecting patients with a network of virtual urologists and medical professionals. Its mobile application facilitates better engagement and navigation through the healthcare system, allowing men to take an active role in improving their health and lifestyle. By streamlining access to specialized care, Bastion Health not only optimizes health outcomes for patients but also presents significant cost savings for employers.

Cingulate Therapeutics, LLC is a biopharmaceutical company focused on developing innovative treatments for central nervous system and neurobiological disorders, particularly Attention Deficit and Hyperactivity Disorder (ADHD). Established in 2012 and headquartered in Kansas City, Kansas, with an additional office in Morristown, New Jersey, Cingulate is advancing two first-line stimulant medications, CTx-1301 and CTx-1302, designed for comprehensive patient use across all age groups. Utilizing a unique delivery technology, these medications aim to provide rapid onset of action, extended duration of effect, and favorable tolerability in a once-daily oral formulation. The company has partnered with Catalent Pharma Solutions to leverage their OptiDose technology, enhancing manufacturing efficiency and drug delivery. Cingulate's approach addresses significant gaps in the current ADHD treatment landscape, particularly the need for full-day therapeutic efficacy, and targets a substantial market opportunity projected to be worth $2-$3 billion in the combination-dose segment and $9 billion overall.

Likarda is a biotech company focused on advancing cell therapies through innovative delivery technologies. Its proprietary Core-Shell Spherification® platform utilizes biocompatible hydrogel materials, such as Hyaluronic Acid and PEG, to create customizable microcapsules that house cell-based therapies. This platform addresses the unique requirements of various cell therapies, enabling applications in the treatment of diabetes, osteoarthritis, and joint pain. For diabetes, Likarda is developing methods to deliver islet-like cells, which have shown promising results in pre-clinical testing with animal models. In the case of osteoarthritis, encapsulated stem cells are designed for injection into the knee, providing a slow-release treatment that alleviates joint pain and promotes healing over several weeks. Likarda's versatility allows for both durable and degradable formulations, enhancing the efficacy of cell-based treatments. The company has gained recognition for its innovation, having been named one of the "50 Most Promising Start-Ups in the World" during Global Entrepreneurship Week, and has secured over $8 million in funding through various sources.